Intelligent Pharmacy最新文献

{"title":"AI-driven insights into the microbiota: Figuring out the mysterious world of the gut","authors":"Abhinandan Patil ,&nbsp;Neha Singh ,&nbsp;Mohsina Patwekar ,&nbsp;Faheem Patwekar ,&nbsp;Anasuya Patil ,&nbsp;Jeetendra Kumar Gupta ,&nbsp;Selvaraja Elumalai ,&nbsp;Nagam Santhi Priya ,&nbsp;Alapati sahithi","doi":"10.1016/j.ipha.2024.08.003","DOIUrl":"10.1016/j.ipha.2024.08.003","url":null,"abstract":"<div><div>This review delves into the fascinating realm of microbial insights enabled by artificial intelligence (AI), unveiling the mysteries of the intricate gut environment. Research into the human microbiome has evolved due to the fast development of AI and Machine learning (ML). Never before have such novel avenues for individualized medical care and therapeutic therapies been available as a result of this. Our first stop is at software developed specifically for microbiome data analysis. Complex datasets can be accessed and valuable information extracted using AI algorithms and machine learning approaches. Next, we take a look at predictive modeling of gut microbial interactions. Here we see how AI can foretell the actions of microorganisms and their effects on host health and illness. Afterwards, we investigate the efficacy of AI in detecting microbe biomarkers, which are crucial indicators of gut health and potential dangers of disease. A disease's root cause can be identified and a treatment strategy developed using this innovative approach. We also delve into the realm of personalized microbiome analysis and demonstrate how AI may assist in making dietary and lifestyle adjustments that are most suited to each individual in order to enhance their health. The impact of AI extends beyond the realm of research and assessment and include the development of novel medications. Our focus is on the ways AI is assisting the hunt for novel probiotics and microbiome-based therapies, which could one day lead to the development of effective remedies for various medical conditions. However, although we anticipate AI's potential, we must equally consider the ethical considerations involved in studying microbiota. This paper highlights the significance of data protection, transparency, and bias reduction in ensuring the responsible and fair use of AI. We can maximize AI's potential without trampling on people's rights or exacerbating existing inequalities if we adhere to ethical guidelines and work to earn the public's trust. Finally, this study demonstrates the potential power of AI-driven microbiome discoveries. By being committed to ethical principles and vigilant in our pursuit of new challenges, we may advance microbiota research toward a future of data-driven, customized healthcare that utilizes AI as a valuable tool for optimal health and wellness.</div></div>","PeriodicalId":100682,"journal":{"name":"Intelligent Pharmacy","volume":"3 1","pages":"Pages 46-52"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143478775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimization of microwave-assisted green synthesis of zinc oxide nanoparticles using Ocimum americanum and Euphorbia hirta extracts: In vitro evaluation of antioxidant, anti-inflammatory, antibacterial, cytotoxicity, and wound healing properties","authors":"J. Nandhini ,&nbsp;E. Karthikeyan ,&nbsp;M. Sheela ,&nbsp;M. Bellarmin ,&nbsp;B. Gokula Kannan ,&nbsp;A. Pavithra ,&nbsp;D. Sowmya Sri ,&nbsp;S. Siva Prakash ,&nbsp;S. Rajesh Kumar","doi":"10.1016/j.ipha.2024.09.003","DOIUrl":"10.1016/j.ipha.2024.09.003","url":null,"abstract":"<div><div>This investigation optimized the microwave-assisted green synthesis of zinc oxide nanoparticles utilizing <em>Ocimum americanum</em> and <em>Euphorbia hirta</em> extracts for enhanced wound healing applications. The synthetic process employed microwave radiation and natural reductants from plant extracts, offering an environmentally benign, cost-effective, and time-efficient approach. Design expert software was utilized to optimize the synthesis, with the concentration of the zinc sulphate precursor, microwave irradiation time, and plant extract ratio as independent variables, and nanoparticle size as the dependent variable. The optimal conditions (12.8 ​mM zinc sulphate, 12 ​min of irradiation, and a 26:1 plant extract ratio) yielded Zinc oxide nanoparticles characterized by UV, SEM, FTIR, XRD, EDX, and zeta-sizer techniques to assess the nanoparticle formation, morphology, functional groups, crystal structure, elemental composition, and stability. The nanoparticles exhibited strong antioxidant activity (90.23% ​± ​0.82% at 50 ​μg/mL), comparable anti-inflammatory effects to diclofenac sodium (86.13% ± ​1.03% at 50 ​μg/mL), significant concentration-dependent antibacterial activity against <em>Staphylococcus aureus</em>, <em>Escherichia coli</em>, and <em>Pseudomonas</em> sp., and effective biofilm inhibition. Time-kill curve assays demonstrated effective bacterial count reduction, while zebrafish embryonic toxicity studies indicated minimal toxicity at lower concentrations (5–20 ​μg/mL) with reduced hatching and survival rates at higher concentrations (40–80 ​μg/mL). Additionally, zinc oxide nanoparticles promoted wound healing <em>in vitro</em> by enhancing fibroblast cell migration and proliferation of mouse fibroblast (3T3-L1) cells. The results elucidate the potential of microwave-assisted green-synthesized zinc oxide nanoparticles incorporating plant extracts in advancing wound care therapies through their multifaceted biological applications.</div></div>","PeriodicalId":100682,"journal":{"name":"Intelligent Pharmacy","volume":"3 1","pages":"Pages 90-109"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143478778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development, optimization, and in-vivo bioavailability study of erlotinib hydrochloride loaded microsponge for colon targeting","authors":"Ayan Kumar Kar ,&nbsp;Beduin Mahanti ,&nbsp;Banhishikha Kar ,&nbsp;Anupam Jana ,&nbsp;Subhasis Chakrabarty ,&nbsp;Smriti Singh ,&nbsp;Subhabrota Majumdar","doi":"10.1016/j.ipha.2024.07.002","DOIUrl":"10.1016/j.ipha.2024.07.002","url":null,"abstract":"<div><div>The present investigation aimed to develop as well as optimize microsponge containing erlotinib hydrochloride (ETB) that was composed of ethyl cellulose (EC) and pectin. The water solubility and enzymatic susceptibility make it easier to fabricate the microsponge formulation. The ETB loaded microsponge was manufactured using quasi-emulsion solvent diffusion process. By this technique, organic solution of the primary component is emulsified with stabilizing agents that are soluble in water. To design the formation of the microsponge, 3² factorial design was implemented. It was investigated how the response variables like particle dimension, entrapment efficiency, ETB diffusion at 12 ​h were influenced by independent variables such as rotation speed and the pectin to ethyl cellulose ratio. The optimal microsponge formulation loaded with ETB (F₀) composed of 1:2.8 ratio of pectin to ethyl cellulose (EC) with stirring rate at 478 ​rpm. Particle dimension, entrapment efficiency, and ETB release at 12 ​h from optimized formulation were shown 104.89 ​± ​0.62 ​nm, 82.36 ​± ​2.85 ​%, and 85.49 ​± ​1.84 ​% respectively. The <em>In-vivo</em> pharmacokinetic study conducted on rabbit model shows a significant improvement in bioavailability. The optimized microsponge formulation has been found to have a higher <em>C</em>_max than the ETB aqueous suspension. The stability of the formulation has been determined by the accelerated stability study of optimized microsponge formulation. This study indicated that the optimized formulation retained its stability even after 90days. In general, the present investigation demonstrated that drug loaded microsponge based formulation is a suitable method to improve the therapeutic efficacy and bioavailability of ETB.</div></div>","PeriodicalId":100682,"journal":{"name":"Intelligent Pharmacy","volume":"3 1","pages":"Pages 1-10"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141715266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Design, optimization, and characterization of Zolmitriptan loaded liposomal gels for intranasal delivery for acute migraine therapy","authors":"A.K. Chettupalli ,&nbsp;Sunand Katta ,&nbsp;Mohd Vaseem Fateh ,&nbsp;M. Akiful Haque ,&nbsp;Daniel Kothapally ,&nbsp;Prasanth Damarasingu ,&nbsp;Budumuru Padmasri ,&nbsp;Palavalasa Archana","doi":"10.1016/j.ipha.2024.07.003","DOIUrl":"10.1016/j.ipha.2024.07.003","url":null,"abstract":"<div><div>Zolmitriptan is the primary drug for the treatment of Migraine. However, the bioavailability of the drug is low and requires repetitive administration leading to side effects. Zolmitriptan's bioavailability can be improved by incorporating it into liposomes as a topical intranasal gel. The formulation was developed using a Central composite design employing a response surface approach. The new formulations were tested for particle size, shape, drug entrapment efficiency, and in vitro drug release. Permeation experiments and histopathology in rats were also conducted to determine the formulation's safety. The vesicle size was found to be in the range of 103.82 ​± ​7.16 to 694.38 ​± ​1.02 ​nm, zeta potential --19.28 to −32.8 ​mV, Entrapment Efficiency from 55.49 ​± ​1.37 to 99.12 ​± ​0.36 %, and cumulative drug release from 59.71 ​± ​6.94 to 99.38 ​± ​0.13 % respectively. In-vitro drug release of G1 and G3 gel formulations showed a non-Fickian released pattern during the studies. A comparison of the permeation coefficient of G1 (0.539 μg/cm2) and G3 (5.3 μg/cm2) showed a slight variation in the drug release rate after 24 ​h. For the liposomal gel and its solution, we found a significant difference in drug penetration of p0.05 after 12 ​h compared to the control gel. There were substantial differences in bioavailability and pharmacokinetics between the optimal Liposomal Gel Formulation and other formulations, including the drug solution, liposomal suspension, and optimized formulation F12. The liposomal gel is non-irritating and safe for topical administration by histopathological investigations. Therefore, the study demonstrated that Zolmitriptan Liposomal gel has better efficacy, good tolerability, and enhanced bioavailability, making it an optimal treatment for acute Migraine.</div></div>","PeriodicalId":100682,"journal":{"name":"Intelligent Pharmacy","volume":"3 1","pages":"Pages 11-25"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141709509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends in research on AI-aided drug discovery from 2009 to 2023: A 15-year bibliometric analysis","authors":"Wenshuo Jiang ,&nbsp;Zhigang Zhao","doi":"10.1016/j.ipha.2024.09.001","DOIUrl":"10.1016/j.ipha.2024.09.001","url":null,"abstract":"<div><h3>Purpose</h3><div>In recent years, the rapid advancement of artificial intelligence technology has brought opportunities for the acceleration and improvement of the drug discovery process by aiding in all stages of drug discovery like drug target identification and validation, virtual screening, de novo drug design, and ADMET property prediction. The present study aims to provide an overview of the developing tendency, cooperation, and influence of academic groups and individuals, hotspots, and crucial problems in the field of AI-aided drug discovery using bibliometric methods.</div></div><div><h3>Methods</h3><div>Publications on AI-aided drug discovery published from January 1, 2009, to December 31, 2023, were retrieved from the Web of Science core collection. The document type was limited to articles or reviews, and the language was set to English. Citespace was used to conduct the bibliometric analysis.</div></div><div><h3>Results</h3><div>A total of 9700 publications were included, and the number of them generally increased over time, with a rapid increase tendency since 2018. The US and China were the leading countries in this field. The Chinese Academy of Sciences was the most influential institution. Ekins, Sean was the most productive author and Hou, Tingjun formed the largest cooperation network. Networks and clusters of keywords highlighted terms like “virtual screening”, “expression” and “drug delivery” as focused topics, and burst analysis showed that “support vector machines”, and “classification” received the longest attention. Meanwhile the keywords “sars cov 2”, “molecular design” and “clinical trials” were hotspots in recent years. The content analysis of the co-cited literature identified the significant questions to be tackled in future research.</div></div><div><h3>Conclusions</h3><div>This study offers a comprehensive landscape of the global contributions given to this increasingly important and prolific field of research and points out several areas that might be addressed by future research to better develop the field of AI-aided drug discovery.</div></div>","PeriodicalId":100682,"journal":{"name":"Intelligent Pharmacy","volume":"3 1","pages":"Pages 71-83"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143478777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of IOT in healthcare: Applications, security & privacy concerns","authors":"","doi":"10.1016/j.ipha.2024.01.003","DOIUrl":"10.1016/j.ipha.2024.01.003","url":null,"abstract":"<div><div>Employing the Internet of Things (IoT) in healthcare provides many advantages for patient monitoring and analysis of the patient's health with the help of generated data. The basic role of IoT in healthcare is to ease the patient's life by giving them a monitor over their medical condition. The use of IoT in medical devices requires a focus on the end-user. Medical devices such as glucose meters are designed to record the data of the patient and their vital signs. The generated information can be used to enhance decision-making for the physician. The collected information about the patient can be at risk due to certain security issues during the transferring of information can compromise the identity and social life of the patient. This review explores the IoT regarding its structural requirement and its role in various fields with special emphasis on healthcare. The security and privacy issues than can hinder the utilization of IoT at its potential and ways to overcome these issues are being addressed.</div></div>","PeriodicalId":100682,"journal":{"name":"Intelligent Pharmacy","volume":"2 5","pages":"Pages 707-714"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139631195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardioprotective potential of Rosuvastatin against isoproterenol induced cardiac dysfunction and hypertrophy in the experimental model of rodents","authors":"","doi":"10.1016/j.ipha.2023.09.002","DOIUrl":"10.1016/j.ipha.2023.09.002","url":null,"abstract":"<div><h3>Aims</h3><div>Cardiovascular disease is the primary cause of mortality and morbidity, and its terminal phase is chronic heart failure. The present study aimed to examine the protective impact of rosuvastatin on isoproterenol-induced chronic heart failure and investigate plausible related mechanisms. Rosuvastatin, a drug with multiple pleiotropic properties, has been examined for its cardioprotective effects in heart failure induced by isoproterenol.</div></div><div><h3>Methods</h3><div>Male Sprague Dawley rats were given isoproterenol 5 ​mg/kg once a day for 7 days to establish heart failure by subcutaneous injection. Simultaneously, rosuvastatin (10 ​mg/kg) was orally administrated from day 1 to day 14. Protective effects were evaluated by heart grading and gross morphology, hemodynamic parameter, cardiac troponin I, heart mitochondrial enzyme and lysosomal hydrolases and pro inflammatory cytokines levels were analyzed.</div></div><div><h3>Results</h3><div>Rosuvastatin (10 ​mg/kg) significantly attenuated isoproterenol-induced hypertrophy, remodeling and dysfunction of the ventricle, reduced the heart mitochondrial enzyme and lysosomal hydrolases and normalized the increased hemodynamic and pro inflammatory cytokines levels.</div></div><div><h3>Conclusions</h3><div>The study highlights the preventive effects of, rosuvastatin, against heart failure. The results of the research indicate that rosuvastatin has cardioprotective effects on the experimental model, which were supported by several characteristics. However, further research is required to identify the precise molecular mechanisms and signalling pathways of rosuvastatin's impact on heart failure.</div></div>","PeriodicalId":100682,"journal":{"name":"Intelligent Pharmacy","volume":"2 5","pages":"Pages 651-661"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135346682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comprehensive evaluation of PD-1 inhibitors marketed in China based on a Quick Guideline for drug evaluation and selection in Chinese Medical Institutions (second edition)","authors":"Long Min ,&nbsp;Zhao Yulan ,&nbsp;Li Wenrui ,&nbsp;Shi Weilin ,&nbsp;Chen Wanyi","doi":"10.1016/j.ipha.2024.07.006","DOIUrl":"10.1016/j.ipha.2024.07.006","url":null,"abstract":"<div><h3>Objective</h3><div>To conduct a comprehensive evaluation of PD-1 inhibitors for the treatment of advanced non-small cell lung cancer on the market in China, using <em>A Quick Guideline for Drug Evaluation and Selection in Chinese Medical Institutions (Second Edition)</em>, and to provide a reference for the selection of and decision-making on clinical drugs in hospitals.</div></div><div><h3>Method</h3><div>The Sanzhi drug evaluation and selection system was used to evaluate the PD-1 inhibitors for the treatment of advanced non-small cell lung cancer on the market in China, according to five characteristics: pharmaceutical characteristics, efficiency, safety, economy, and others.</div></div><div><h3>Results</h3><div>Based on the above evaluation criteria, the scores of all PD-1 inhibitors were above 61 points. The main difference among the five characteristics were efficiency and economy. The difference between the other characteristics was relatively small. Sintilimab injection had the highest score due to the advantages among characteristics except the other attributes. Nivolumab injection (100 mg/10 ​mL (10 ​mg/mL)) had the lowest total score due to its low effectiveness and economy scores.</div></div><div><h3>Conclusion</h3><div>PD-1 inhibitors are effective therapeutic drugs for immunotherapy in patients with advanced non-small cell lung cancer. Different PD-1 inhibitors have different advantages in clinical treatment. The comprehensive evaluation of PD-1 inhibitors for the treatment of advanced non-small cell lung cancer on the market in China through <em>A Quick Guide for Drug Evaluation and Selection of Chinese Medical Institutions (Second Edition)</em> can provide a basis for drug selection and scientific, reasonable, and safe drug use in medical institutions.</div></div>","PeriodicalId":100682,"journal":{"name":"Intelligent Pharmacy","volume":"2 5","pages":"Pages 630-637"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142554111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"AI's role in revolutionizing personalized medicine by reshaping pharmacogenomics and drug therapy","authors":"Hamed Taherdoost ,&nbsp;Alireza Ghofrani","doi":"10.1016/j.ipha.2024.08.005","DOIUrl":"10.1016/j.ipha.2024.08.005","url":null,"abstract":"<div><div>This paper examines the transformative impact of artificial intelligence (AI) on pharmacogenomics, signaling a paradigm shift in personalized medicine. With a focus on enhancing drug response prediction and treatment optimization, AI, particularly machine learning and deep learning algorithms, navigates the complexity of genomic data. By elucidating intricate relationships between genetic factors and drug responses, AI augments the identification of genetic markers and contributes to the development of comprehensive models. The review emphasizes AI's role in guiding treatment decisions, minimizing adverse reactions, and optimizing drug dosages in clinical settings. Ethical considerations, challenges, and future directions are also discussed. This work underscores the synergy of AI and pharmacogenomics, offering a more effective and patient-centric approach to drug therapy, marking a significant advancement in the field of personalized medicine.</div></div>","PeriodicalId":100682,"journal":{"name":"Intelligent Pharmacy","volume":"2 5","pages":"Pages 643-650"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142554113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Removal notice to “Ziziphus mauritiana: An in-depth review of its medicinal attributes and pharmacological activities” [Intell. Pharm. 2 (2024) 274–283]","authors":"Deepak Jha ,&nbsp;Pallavi Hangargekar ,&nbsp;Md Akbar ,&nbsp;Ashish Singh Parihar ,&nbsp;Saurabh Kashyap ,&nbsp;Amol Joshi ,&nbsp;Md Azizur Rahman","doi":"10.1016/j.ipha.2024.07.005","DOIUrl":"10.1016/j.ipha.2024.07.005","url":null,"abstract":"","PeriodicalId":100682,"journal":{"name":"Intelligent Pharmacy","volume":"2 5","pages":"Page 744"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142552093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}